Abstract:TDP-43 is an aggregation-prone protein which accumulates in the hallmark pathological inclusions of amyotrophic lateral sclerosis (ALS). However, the analysis of deeply phenotyped human post-mortem samples has shown that TDP-43 aggregation, revealed by standard antibody methods, correlates poorly with symptom manifestation. Recent identification of cryptic-splicing events, such as the detection of Stathmin-2 ( STMN-2 ) cryptic exons, are providing evidence implicating TDP-43 loss-of-function as a potential driving pathomechanism but the temporal nature of TDP-43 loss and its relation to the disease process and clinical phenotype is not known. To address these outstanding questions, we used a novel RNA aptamer, TDP-43 APT , to detect TDP-43 pathology and used single molecule in situ hybridization to sensitively reveal TDP-43 loss-of-function and applied these in a deeply phenotyped human post-mortem tissue cohort. We demonstrate that TDP-43 APT identifies pathological TDP-43, detecting aggregation events that cannot be detected by classical antibody stains. We show that nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology. Crucially, we show that these pathological features of TDP-43 loss-of-function precede the clinical inflection point and are not required for region specific clinical manifestation. Furthermore, we demonstrate that gain-of-function in the form of extensive cytoplasmic accumulation, but not loss-of-function, is the primary molecular correlate of clinical manifestation. Taken together, our findings demonstrate implications for early diagnostics as the presence of STMN-2 cryptic exons and early TDP-43 aggregation events could be detected prior to symptom onset, holding promise for early intervention in ALS.

HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases

TDP-43 proteinopathies: a new wave of neurodegenerative diseases

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD

TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD

TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTD

Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease

Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD

Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols

Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice

TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A

Aberrant neural activity in prefrontal pyramidal neurons lacking TDP-43 precedes neuron loss

TDP43 proteinopathy exhibits disease, tissue, and context-specific cryptic splicing signatures

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis

pTDP-43 levels correlate with cell type specific molecular alterations in the prefrontal cortex of ALS/FTD patients

A transient protein folding response targets aggregation in the early phase of TDP-43-mediated neurodegeneration

Neuronal TDP-43 depletion affects activity-dependent plasticity

14-3-3θ, a novel player in TDP-43 pathophysiology: Implications for ALS/FTD

TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes

Molecular Visualization of Neuronal TDP43 Pathology In Situ

RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS